MICE SENSITIVITY ANALYSIS OF EVENT FREE SURVIVAL IN HIGH-RISK NEUROBLASTOMA PATIENTS RECEIVING EFLORNITHINE (DFMO) MAINTENANCE TREATMENT WITH MATCHED EXTERNAL CONTROLS

被引：0
|
作者：
Kraveka, Jacqueline [1 ]
Oesterheld, Javier [2 ]
Ferguson, William [3 ,4 ]
Bergendahl, Genevieve [5 ]
Clinch, Thomas [6 ]
Staines, Harry [6 ]
Sholler, Giselle Saulnier [2 ]
机构：
[1] MUSC Shawn Jenkins Childrens Hosp, Pediat Hematol Oncol, Charleston, SC USA
[2] Atrium Hlth Levine Childrens Hosp, Pediat Hematol & Oncol, Charlotte, NC USA
[3] St Louis Univ, Sch Med, St Louis, MO USA
[4] St Louis Univ, Cardinal Glennon Childrens Med Ctr, Dept Pediat, Div Hematol Oncol, St Louis, MO USA
[5] Beat Childhood Canc Res Consortium, Charlotte, NC USA
[6] US WorldMeds, Biostats, Louisville, KY USA
来源：
PEDIATRIC BLOOD & CANCER | 2023年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP335
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SENSITIVITY ANALYSES OF EVENT FREE AND OVERALL SURVIVAL IN HIGH-RISK NEUROBLASTOMA PATIENTS RECEIVING DFMO MAINTENANCE TREATMENT WITH MATCHED EXTERNAL CONTROLS INCLUDING MYCN
    Sholler, Giselle Saulnier
    Bergendahl, Genevieve
    Ferguson, William
    Clinch, Thomas
    Lorenzi, Elizabeth
    Berry, Donald
    Oesterheld, Javier
    Brown, Valerie
    Eslin, Don
    Hanson, Derek
    Harrod, Virginia
    Isakoff, Michael
    Mitchell, Deanna
    Roberts, William
    Wada, Randal
    Zage, Peter
    Kraveka, Jacqueline
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S90 - S91
  • [2] Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance.
    Oesterheld, Javier E.
    Bergendahl, Genevieve
    Berry, Donald A.
    Lorenzi, Elizabeth
    Clinch, Thomas
    Kraveka, Jacqueline M.
    Ferguson, William
    Brown, Valerie I.
    Eslin, Don
    Hanson, Derek
    Harrod, Virginia Lynn
    Isakoff, Michael
    Mitchell, Deanna
    Wada, Randal
    Zage, Peter E.
    Sholler, Giselle Linda Saulnier
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] COMPARISON OF EVENT FREE SURVIVAL (EFS) IN HIGH-RISK NEUROBLASTOMA (HRNB) PATIENTS RECEIVING EFLORNITHINE (DFMO) MAINTENANCE TO AN EXTERNAL CONTROL IMMUNOTHERAPY STUDY DATABASE
    Oesterheld, Javier
    Bergendahl, Genevieve
    Berry, Donald
    Lorenzi, Elizabeth
    Clinch, Thomas
    Kraveka, Jacqueline
    Ferguson, William
    Brown, Valerie
    Eslin, Don
    Hanson, Derek
    Harrod, Virginia
    Isakoff, Michael
    Mitchell, Deanna
    Wada, Randy
    Zage, Peter
    Sholler, Giselle Saulnier
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [4] Survival outcomes in patients with high-risk neuroblastoma (HRNB) in remission after relapsed or refractory treatment receiving eflornithine (DFMO) maintenance.
    Sholler, Giselle Linda Saulnier
    Ferguson, William
    Bergendahl, Genevieve
    Clinch, Thomas
    Kraveka, Jacqueline M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] TOLERABILITY AND SAFETY OF EFLORNITHINE (DFMO) IN HIGH-RISK NEUROBLASTOMA (HRNB) PATIENTS TREATED WITH DFMO MAINTENANCE THERAPY
    Bergendahl, Genevieve
    Kraveka, Jacqueline
    Ferguson, William
    Moore, Abigail
    Clinch, Thomas
    Oesterheld, Javier
    Wada, Randal
    Isakoff, Michael
    Eslin, Don
    Brown, Valerie
    Roberts, William
    Zage, Peter
    Harrod, Virginia
    Mitchell, Deanna
    Hanson, Derek
    Sholler, Giselle Saulnier
    PEDIATRIC BLOOD & CANCER, 2023, 70
  • [6] Event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance treatment based on a retrospective, blinded independent central review (BICR) of imaging during long-term follow-up
    Oesterheld, Javier E.
    Bergendahl, Genevieve
    Clinch, Thomas
    Gullo, Kristen
    Staines, Harry
    Bohl, Casey E.
    Kraveka, Jacqueline M.
    Ferguson, William
    Sholler, Giselle Linda Saulnier
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons
    Oesterheld, Javier
    Ferguson, William
    Kraveka, Jacqueline M.
    Bergendahl, Genevieve
    Clinch, Thomas
    Lorenzi, Elizabeth
    Berry, Don
    Wada, Randal K.
    Isakoff, Michael S.
    Eslin, Don E.
    Brown, Valerie I.
    Roberts, William
    Zage, Peter
    Harrod, Virginia L.
    Mitchell, Deanna S.
    Hanson, Derek
    Sholler, Giselle L. Saulnier
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (01) : 90 - +
  • [8] Overall survival and event free survival in patients with high-risk neuroblastoma after targeted therapy
    Mazankova, D.
    Mazanek, P.
    Maskova, V.
    Tinka, P.
    Kyr, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (06) : 1546 - 1546
  • [9] Event-free survival of patients with high-risk neuroblastoma treated with an N6-like induction treatment
    Valteau-Couanet, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 6262 - 6263
  • [10] A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma
    Lewis, Elizabeth C.
    Kraveka, Jacqueline M.
    Ferguson, William
    Eslin, Don
    Brown, Valerie, I
    Bergendahl, Genevieve
    Roberts, William
    Wada, Randal K.
    Oesterheld, Javier
    Mitchell, Deanna
    Foley, Jessica
    Zage, Peter
    Rawwas, Jawhar
    Rich, Maria
    Lorenzi, Elizabeth
    Broglio, Kristine
    Berry, Donald
    Sholler, Giselle L. Saulnier
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (11) : 3152 - 3159
12345